2001:
Rwanda becomes the second country in the Sub-Sahara region to benefit from the UN/Industry Accelerating Access Initiative, an agreement signed in May 2000 by UNAIDS, WHO, the UN Population Fund and five pharmaceutical companies including Merck Sharp & Dohme to reduce the prices of  HIV drugs in developing countries so more patients will be able to access them. As a result of this initiative, the prices of branded ARV triple therapy in Rwanda drop from $400 per month (200,000 RwF)* to less than $50 (25,000 RwF)* per month. Since then the prices have further decreased to less than $25 (14.500 RwF)** per month for paying patients. In the near future, the Rwandan Government would like to see the price of ARVs drop to $10 per month (at the current exchange rate).

2002:
1^st HIV programs funded by international donors

2003:

• Creation of the Kigali-based Treatment and Research Aids Center (TRAC), by Rwanda's National Government for the purpose of conducting national HIV/AIDS surveillance and providing technical assistance to the public and private sectors in the prevention, testing and clinical treatment of HIV/AIDS in the country.
• Decentralization of access to ARVs throughout the country begins so these life-saving drugs can be available to HIV-positive patients outside of Kigali.
• Rwandan Government commits to subsidizing the costs of ARVs for people making under 50,000 RwF ($ 86)**  a month.

2004:
Funds committed by international donors to subsidize ARV treatment for patients throughout the country who cannot afford it, begin to make an impact.